Cargando…

Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens

Prostate cancer (PCa) is the most common cancer in men and the second most common cause of cancer-related death in men. In recent years, novel therapeutic options for PCa have been developed and studied extensively in clinical trials. Sipuleucel-T is the first cell-based immunotherapeutic vaccine fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Westdorp, Harm, Sköld, Annette E., Snijer, Berit A., Franik, Sebastian, Mulder, Sasja F., Major, Pierre P., Foley, Ronan, Gerritsen, Winald R., de Vries, I. Jolanda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018526/ https://www.ncbi.nlm.nih.gov/pubmed/24834066 http://dx.doi.org/10.3389/fimmu.2014.00191

Ejemplares similares

Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy
por: Gerritsen, Winald R., et al.
Publicado: (2011)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
por: Tel, Jurjen, et al.
Publicado: (2016)

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013)

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
por: Boudewijns, Steve, et al.
Publicado: (2016)

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Opportunities for immunotherapy in microsatellite instable colorectal cancer
por: Westdorp, Harm, et al.
Publicado: (2016)

Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
por: Wimmers, Florian, et al.
Publicado: (2014)

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
por: Westdorp, Harm, et al.
Publicado: (2019)

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
por: van Willigen, Wouter W., et al.
Publicado: (2018)

Lactate dehydrogenase: a marker of diminished antitumor immunity
por: Van Wilpe, Sandra, et al.
Publicado: (2020)

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder
por: van Wilpe, Sandra, et al.
Publicado: (2020)

PTEN Hamartoma Tumor Syndrome and Immune Dysregulation()()()
por: Eissing, Marc, et al.
Publicado: (2018)

Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy
por: Mathan, Till S.M., et al.
Publicado: (2017)

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer
por: Beer, Tomasz M, et al.
Publicado: (2015)

Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer
por: Kiessling, Andrea, et al.
Publicado: (2012)

Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma
por: Boudewijns, Steve, et al.
Publicado: (2014)

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
por: Privé, Bastiaan M., et al.
Publicado: (2021)

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
por: Boudewijns, Steve, et al.
Publicado: (2020)

Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
por: van der Doelen, Maarten J., et al.
Publicado: (2021)

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
por: Li, Jian, et al.
Publicado: (2018)

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2021)

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets
por: Sittig, Simone P., et al.
Publicado: (2016)

Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets
por: Sköld, Annette E., et al.
Publicado: (2015)

Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody
por: Muthumani, Kar, et al.
Publicado: (2017)

The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review
por: Martin, Felicity C., et al.
Publicado: (2023)

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells
por: van Dodewaard-de Jong, Joyce M., et al.
Publicado: (2015)

Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
por: Santegoets, Saskia JAM, et al.
Publicado: (2014)

Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
por: Kleinendorst, Simone C., et al.
Publicado: (2022)

Mild Hypogammaglobulinemia Can Be a Serious Condition
por: Janssen, Lisanne M. A., et al.
Publicado: (2018)

Tumor Immunotherapy: Lessons from Autoimmunity
por: Maueröder, Christian, et al.
Publicado: (2014)

A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant
por: Abdallah, Al-Ola, et al.
Publicado: (2018)

Improving cancer immunotherapy by targeting the STATe of MDSCs
por: de Haas, Nienke, et al.
Publicado: (2016)

Dual-Phase PET-CT to Differentiate [(18)F]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in Patients with Prostate Cancer
por: Oprea-Lager, Daniela E., et al.
Publicado: (2012)

Intravenous administration of the conditionally replicative adenovirus Ad5-Δ24RGD induces regression of osteosarcoma lung metastases
por: Graat, Harm CA, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_jm4io68bmsnenbur5ad8na7qop